BOTHELL, Wash. -- On Dec. 11, Eden Bioscience Corp. received a Nasdaq Staff Deficiency Letter from the Nasdaq Stock Market notifying it that the closing price per share for the Company's common stock was below the $1 minimum bid price requirement for 30 consecutive trading days.

As a result, the letter said, the company no longer meets The Nasdaq Capital Market's minimum bid price requirement for continued listing set forth in Marketplace Rule 4310(c)(4).

Nasdaq has provided the company with 180 calendar days, or until June 11, 2007, to regain compliance. To regain compliance with the minimum bid price requirement, the closing bid price of the Company's common stock must remain above $1 for a minimum of 10 consecutive trading days. If the company does not regain compliance by June 11, 2007, and is not eligible for an additional 180-day compliance period, Eden Bioscience's common stock will be delisted from The Nasdaq National Market.

The 180-day compliance period relates exclusively to the Company's bid price deficiency. The company may be delisted during the 180-day period for failure to maintain compliance with any other listing requirement which occurs during this period.

Eden Bioscience management and Board of Directors are considering various alternatives to address this issue.

Eden Bioscience is a plant technology company focused on developing, manufacturing and marketing innovative, natural protein-based products for agriculture.Its products are based on naturally occurring proteins called "harpins," which activate a plant's intrinsic ability to protect itself through growth and stress-defense responses.

SOURCE: Eden Bioscience Corporation via Market Wire.